Compare FULT & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FULT | TWST |
|---|---|---|
| Founded | 1882 | 2013 |
| Country | United States | United States |
| Employees | 3400 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | N/A | 2018 |
| Metric | FULT | TWST |
|---|---|---|
| Price | $20.60 | $49.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 8 |
| Target Price | $21.40 | ★ $45.75 |
| AVG Volume (30 Days) | ★ 1.9M | 970.6K |
| Earning Date | 04-14-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.74% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | $6.39 | $18.91 |
| Revenue Next Year | $5.52 | $15.07 |
| P/E Ratio | $10.58 | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $14.33 | $23.30 |
| 52 Week High | $22.99 | $57.88 |
| Indicator | FULT | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 55.38 | 57.26 |
| Support Level | $19.05 | $41.65 |
| Resistance Level | $21.01 | $57.88 |
| Average True Range (ATR) | 0.50 | 2.82 |
| MACD | 0.12 | 0.28 |
| Stochastic Oscillator | 92.11 | 86.48 |
Fulton Financial Corp is a U.S.-based financial services holding company that operates in five states: Pennsylvania, Delaware, Maryland, New Jersey and Virginia. It offers a range of consumer and commercial banking products and services, such as checking and savings deposit products and loan products. It offers consumer and commercial banking products and services, as well as wealth management products and services. The bank derives its revenue from non-interest income, led by its Wealth Management division.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.